12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-27), Arcus Biosciences's 12-1 Month Momentum % is -7.45%.
The industry rank for Arcus Biosciences's 12-1 Month Momentum % or its related term are showing as below:
RCUS's 12-1 Month Momentum % is ranked better than 60.36% of 1481
companies
in the Biotechnology industry
Industry Median: -20.83
vs RCUS: -7.45
Competitive Comparison of Arcus Biosciences's 12-1 Month Momentum %
For the Biotechnology subindustry, Arcus Biosciences's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcus Biosciences's 12-1 Month Momentum % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arcus Biosciences's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Arcus Biosciences's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Arcus Biosciences 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Arcus Biosciences's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Arcus Biosciences (Arcus Biosciences) Business Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RCUS has been successfully added to your